NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
Clinical Trials
41 trialsNCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT02507336 2024-08-01
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
Phase 2 Completed
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT00966693 2020-11-04
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00041080 2019-07-30
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00310076 2018-08-23
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00287872 2018-03-01
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01057225 2017-12-12
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00307294 2017-11-24
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
University of Pittsburgh
Phase 2 Completed
NCT00081939 2017-10-17
UARK 2003-33, Total Therapy III
University of Arkansas
Phase 2 Completed
NCT00222105 2017-07-02
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
University of Kansas Medical Center
Phase 2 Completed
NCT00097981 2017-04-07
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00523848 2017-02-23
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT00040937 2016-12-08
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00450801 2015-11-10
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
University of Miami
Phase 2 Completed
NCT00577096 2015-04-06
Effects of Exercise in Combination With Epoetin Alfa
University of Arkansas
Phase NA Completed
NCT00098865 2014-10-07
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00357500 2014-10-01
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00142116 2014-06-02
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00096018 2013-10-24
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT00379353 2013-02-04
The Effects of Thalidomide on Symptom Clusters
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00432458 2012-07-04
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 3 Completed
NCT00412542 2012-02-28
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00531453 2012-01-26
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed